SOURCE Cantel Medical Corp.
Room Temperature Process Enhances Innovation Potential for Medical Device Manufacturers
LITTLE FALLS, N.J., Feb. 25, 2014 /PRNewswire/ -- Cantel Medical Corp. (NYSE: CMN) announces that the REVOX® Sterilization Solutions business is now registered to the EN ISO 13485:2003 quality standards. The room temperature, Peracetic Acid/Hydrogen Peroxide (PAA) vacuum vapor process enables effective sterilization of heat and/or chemical sensitive medical, drug delivery, diagnostic, and implantable devices that may not be well-suited to other sterilization processes.
Collaboratively developed and marketed by Cantel subsidiaries Medivators and Mar Cor Purification, REVOX Sterilization Solutions offers the first commercially available room temperature vapor sterilization process. With full contract validation and sterilization services as well as on-site processing potential with multiple chamber configurations, REVOX Sterilization Solutions is positioned to foster increased innovation and production efficiencies for manufacturers of advanced devices.
Jorgen Hansen, COO of Cantel Medical says, "We have seen REVOX Sterilization Solutions solve customer issues that have impeded critical product launch plans. With increasing sophistication of medical, diagnostic, drug delivery, and implantable devices, it's a timely solution for these manufacturers. This ISO registration reflects our attention to quality within all of our business segments and underscores our new product and market expansion capabilities within and between our business groups."
For more information, please visit our website at www.revoxsterilization.com.
About Cantel Medical Corp.
Cantel Medical Corp. (NYSE: CMN) is a leading provider of infection prevention and control products in the healthcare market. Our products include water purification equipment, sterilants, disinfectants and cleaners, specialized medical device reprocessing systems for endoscopy and renal dialysis, terminal sterilization equipment and services, disposable infection control products primarily for dental and GI endoscopy markets, dialysate concentrates and other dialysis supplies, hollow fiber membrane filtration and separation products for medical and non-medical applications, and specialty packaging for infectious and biological specimens. We also provide technical maintenance for our products and offer compliance training services for the transport of infectious and biological specimens. Visit our website at www.cantelmedical.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including, without limitation, the risks detailed in Cantel's filings and reports with the Securities and Exchange Commission. Such forward-looking statements are only predictions, and actual events or results may differ materially from those projected or anticipated.
©2012 PR Newswire. All Rights Reserved.